Current dosage and schedule issues in the development of paclitaxel (Taxol).
Current dosage and schedule issues in the development of paclitaxel (Taxol).
复制标题
目前紫杉醇（Taxol）开发中的剂量和时间表问题。
作者：
S. Arbuck;R. Canetta;N. Onetto;M. Christian
关于抗癌药物给药的最佳剂量和时间表的基本问题经常在药物的监管批准和商业可用性之后长期存在。对于紫杉醇（TAXOL），这些问题在药物开发的早期就被考虑过。本文综述了评估不同药物浓度和药物暴露持续时间的临床前研究。旨在帮助解决这些问题的临床试验的现状也进行了审查。
Basic questions regarding optimal dose and schedule of anticancer drug administration frequently persist long after regulatory approval and commercial availability of a drug. For paclitaxel (TAXOL), these questions were considered early in drug development. This paper reviews the available preclinical studies that assessed different drug concentrations and durations of drug exposure. The current status of clinical trials designed to help resolve these issues is also reviewed.